Palvella Therapeutics, Inc. Partners' Capital Account, Units, Sold in Private Placement
Palvella Therapeutics, Inc. (PVLA) reported Partners' Capital Account, Units, Sold in Private Placement of 8.19 million shares for the 1-month period ending 2016-06-30, per its 10-Q filed 2017-11-13.
Discontinued
us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement · last filed 2017-11-13
- 2016-06-30: Partners' Capital Account, Units, Sold in Private Placement 1 month 8.19M shares.
| Period end | Partners' Capital Account, Units, Sold in Private Placement 1 month |
|---|---|
| 2016-06-30 | 8.19M shares 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |